Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved.
Agreement includes payment of $27.5 million to Oxford, royalty free license to QIAGEN and dismissal of all pending litigation |
| [15-December-2017] |
| GERMANTOWN, Maryland and HILDEN, Germany, December 15, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Limited (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN’s QuantiFERON(R)-TB Gold and QuantiFERON(R)-TB Gold Plus products. Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million. The settlement includes general releases of all parties with no admissions of wrongdoing. This agreement does not affect QIAGEN’s adjusted EPS outlook for the fourth quarter and full-year 2017 since these one-time costs are excluded from adjusted results. Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/20171215_QGEN_OXFD?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/20171215_QGEN_OXFD?sc_lang=en Contacts: QIAGEN Investor Relations John Gilardi +49-2103-29-11711 e-mail: ir@QIAGEN.com Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: pr@QIAGEN.com
SOURCE QIAGEN | ||
Company Codes: Frankfurt:QIA, NASDAQ-NMS:QGEN, Bloomberg:QGEN@US, Bloomberg:QIA@GR, RICS:QGEN.F, ISIN:NL0000240000, NASDAQ-NMS:OXFD |
